A clinical case of amiodarone- and statin-induced neuropathy with a manifestation of chronic inflammatory demyelinating polyneuropathy

DOI: https://doi.org/10.29296/25877305-2023-03-17
Issue: 
3
Year: 
2023

Professor L. Zaslavskii(1, 2), MD; E. Zaslavskaya(1, 2), Candidate of Medical Sciences; M. Petrov(2); E. Skornyakova(2)
1-I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health
of Russia
2-Leningrad Regional Clinical Hospital, Saint Petersburg

The paper analyzes the data available in the scientific literature on the frequency and manifestations of the neurotoxic effect of amiodarone and statins on the peripheral nervous system. It shows the need for a differential diagnosis with immune-mediated polyneuropathies. The authors provide a rationale for the early identification of the neurotoxicity of the drugs to minimize neurological complications. The paper describes a clinical case of a 72-year-old male patient who received amiodarone and statins and developed demyelinating polyneuropathy. Amiodarone discontinuation led to a significant regression of neurological complaints.

Keywords: 
neurology
cardiology
amiodarone neurotoxicity
statin neurotoxicity
drug-induced neuropathy
chronic inflammatory demyelinating polyneuropathy



References: 
  1. Goedee H.S., Attarian S., Kuntzer T. et al. Iatrogenic immune-mediated neuropathies: diagnostic, epidemiological and mechanistic uncertainties for causality and implications for clinical practice. J Neurol Neurosurg Psychiatry. 2021; 92 (9): 975–82. DOI: 10.1136/jnnp-2019-321663
  2. Colvin L.A. Chemotherapy-induced peripheral neuropathy (CIPN): where are we now? Pain. 2019; 160 (Suppl 1): S1–S10. DOI: 10.1097/j.pain.0000000000001540
  3. Jones M.R., Urits I., Wolf J. et al. Drug-induced peripheral neuropathy: a narrative review. Curr Clin Pharmacol. 2020; 15 (1): 38–48. DOI: 10.2174/1574884714666190121154813
  4. Iqbal Z., Bashir B., Ferdousi M. et al. Lipids and peripheral neuropathy. Curr Opin Lipidol. 2021; 32 (4): 249–57. DOI: 10.1097/MOL.0000000000000770
  5. Pathak N.N., Balaganur V., Lingaraju M.C. et al. Atorvastatin attenuates neuropathic pain in rat neuropathy model by down-regulating oxidative damage at peripheral, spinal and supraspinal levels. Neurochemistry International. 2014; 68: 1–9. DOI: 10.1016/j.neuint.2014.01.014
  6. Graveline D. Adverse Effects of statin drugs: a physician patient’s perspective. J Am Phys Surg. 2015; 20: 7–11.
  7. Svendsen T.K., Krøigård T., Wirenfeldt M. et al. Statin use and peripheral nerve function – A prospective follow-up study. Basic Clin Pharmacol Toxicol. 2020; 126 (3): 203–11. DOI: 10.1111/bcpt.13320
  8. Сивякова О.Н., Шманова Н.Ю., Дулеба А.П. Случай множественных побочных эффектов амиодарона. Consilium Medicum. 2018; 20 (5): 71–4 [Sivyakova O.N., Shmanova N.Y., Duleba A.P. A clinical case of multiple amiodarone side effects development. Consilium Medicum. 2018; 20 (5): 71–4 (in Russ.)]. DOI: 10.26442/2075-1753_2018.5.71-74
  9. Jain K.K. Drug-induced peripheral neuropathies. Drug-induced neurological disorders. Springer, Cham, 2021; рр. 437–67.
  10. Пизова Н.В. Основные метаболические и токсические прлинейропатии в клинической практике. Медицинский совет. 2021; 19: 134–46 [Pizova N.V. Main metabolic and toxic polyneuropathies in clinical practice. Medical Council. 2021; 19: 134–46 (in Russ.)]. DOI: 10.21518/2079-701X-2021-19-134-146
  11. Mach F. et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019; 290: 140–205. DOI: 10.1016/j.atherosclerosis.2019.08.014
  12. Ситкали И.В., Чиричкин А.С., Колоколов О.В. Поражение периферической нервной системы, ассоциированное с приемом лекарственных средств. Лечащий Врач. 2019; 5: 19 [Sitkali I.V., Chirichkin A.S., Kolokolov O.V. Affection of peripheral nervous system associated with drug taking. Lechaschi Vrach. 2019; 5: 19 (in Russ.)].
  13. Siao P., Kaku M. A clinician's approach to peripheral neuropathy. Semin Neurol. 2019; 39 (5): 519–30. DOI: 10.1055/s-0039-1694747
  14. Скорнякова Е.А., Заславский Л.Г., Лапин С.В. и др. Опыт определения антител к ганглиозидам при воспалительных полиневропатиях. Журнал неврологии и психиатрии им. С.С. Корсакова. 2019; 119 (5-2): 268–9 [Skornyakova E.A., Zaslavskii L.G., Lapin S.V. et al. Opyt opredeleniya antitel k gangliozidam pri vospalitel'nykh polinevropatiyakh. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2019; 119 (5-2): 268–9 (in Russ.)].
  15. Ryan M., Ryan S.J. Chronic inflammatory demyelinating polyneuropathy: considerations for diagnosis, management, and population health. Am J Manag Care. 2018; 24 (17 Suppl.): S371–9.